|
(ÁÖ)â½ÅÅ×Å© |
¿µ¾÷ºÎÆÀÀå
°æºÏ °æÁֽà | ´ëÇÐ(2~3³â) ÀçÇÐ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
3³â¡è |
ä¿ë½Ã |
12.13 |
|
|
(ÁÖ)¸Þµð½êÀÌ |
(ÁÖ)¸Þµð½êÀÌ À繫 ȸ°è´ã´çÀÚ
°æ±â ÀÇÁ¤ºÎ½Ã | Çз¹«°ü |
À繫/ȸ°è/IR/ÀÚ±Ý/°¨»ç |
3³â¡è |
»ó½Ãä¿ë |
06.18 |
|
|
(ÁÖ) ÇǺêÆ®·Î |
º´¿ø¿µ¾÷ (¼Ò¾Æû¼Ò³â°ú, À̺ñÀÎÈÄ°ú) °æ·Â 3³â ÀÌ»óÀÚ ¸ðÁý
Àü±¹ Àü±¹ | ´ëÇÐ(2~3³â) ÀçÇÐ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
3³â¡è |
ä¿ë½Ã |
03.28 |
|
|
³ª¿ìÇÇÇà |
±¹³»´ë±â¾÷-¹ÙÀÌ¿À½Ã¹Ð·¯ ÇØ¿Ü RA & ¶óÀ̼¾½Ì
¼¿ï Áß±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
3³â¡è |
ä¿ë½Ã |
04.02 |
|
|
(ÁÖ)ÀÌÁö¸ÞµðÄÄ |
(ÁÖ)ÀÌÁö¸ÞµðÄÄ Á¦¾à Æ÷ÀåÀç ±¸¸Å ´ã´çÀÚ Ã¤¿ë
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
»ý»êÁö¿ø/¹°·ù/±¸¸Å |
3³â¡è |
ä¿ë½Ã |
05.17 |
|
|
(ÁÖ)À§µå¹ÙÀÌ¿ÀÄÚ½ºÆÊ |
ºÐ¼®¿¬±¸¿ø
¼¿ï ³ë¿ø±¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
3³â¡è |
ä¿ë½Ã |
05.30 |
|
|
¶óÀÎÆÊ |
ºÎ»ê ÀüÁö¿ª | ´ëÇÐ(2~3³â) ÀçÇÐ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
3³â¡è |
ä¿ë½Ã |
03.31 |
|
|
³ª³ë¸ÞµðÄ® |
º´¿ø¿¡¼ ÈÀåÇ° ¿µ¾÷ÇÏ½Ç ³²,¿© Á÷¿øºÐ ¸ðÁýÇÕ´Ï´Ù.
ºÎ»ê ÇØ¿î´ë±¸ | Çз¹«°ü |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
3³â¡è |
ä¿ë½Ã |
08.11 |
|
|
(ÁÖ)ÀÎÅÍ¿¥µð |
¼öÀÔ ÀÇ·á±â±â ÀÎÇã°¡ ÄÁ¼³ÅÏÆ®¸¦ ¸ð½Ê´Ï´Ù.
¼¿ï ¼ºµ¿±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
3³â¡è |
»ó½Ãä¿ë |
10.07 |
|
|
¶óÀÎÆÊ |
Á¾ÇÕº´¿ø¹× º´¿ø ¿µ¾÷ °æ·ÂÀÚ
ºÎ»ê ÀüÁö¿ª | ´ëÇÐ(2~3³â) ÀçÇÐ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
3³â¡è |
ä¿ë½Ã |
07.29 |
|
|
ÆÄ·º¼¿ ÄÚ¸®¾Æ |
ÆÄ·º¼¿ ÄÚ¸®¾Æ - Clinical Lead
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
4³â¡è |
ä¿ë½Ã |
09.13 |
|
|
ÆĶó°ïÄÁ¼³Æà |
In-Licensing ´ã´ç ´ë¸®/°úÀå(Àç¹ú±×·ìÁ¦¾àȸ»ç)
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
¶óÀ̼¾½ºIn/Out |
3³â¡è |
ä¿ë½Ã |
05.31 |
|
|
ºê·¹ÀÎÇãºê |
(ÇìµåÇåÆÃ)¼¼°è ÃÖ´ëÀÇ ¼ö¼ú¿ë ÀÇ·á±â±â ȸ»ç Reimbursement
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
3³â¡è |
ä¿ë½Ã |
09.15 |
|
|
(ÁÖ)¾¾¾Ø¾¾ |
ÀÇ·á±â±âÆǸſµ¾÷(ÆÀÀå±Þ: ¼Ãʵ¿±Ù¹«)
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
3³â¡è |
ä¿ë½Ã |
12.03 |
|
|
ÆÄ·º¼¿ ÄÚ¸®¾Æ |
ÆÄ·º¼¿ ÄÚ¸®¾Æ - Clinical Lead
¼¿ï °ºÏ±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
4³â¡è |
ä¿ë½Ã |
10.18 |
|